Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Valeant Pharmaceuticals
Valeant Pharmaceuticals
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Olon strengthens market position with acquisitions ahead of CPHI Milan
Two new acquisitions expand Olon’s service offerings and production capacity
Improving the sustainability of pharmaceutical freeze drying with ECO Mode
Freeze dryers are typically associated with high levels of energy consumption; to counteract this issue, GEA Pharma & Healthcare has introduced the LYOVAC ECO Mode, which...
Microbial identification of drug contamination: MALDI-TOF MS as an efficient alternative
This article describes the growing need for fast and accurate microbial detection in the pharmaceutical manufacturing supply chain
Almac Group announces £11m investment to expand global analytical services
The Almac Group has announced an £11m investment and the creation of more than 100 new jobs to expand its global analytical services capabilities
Neopac unveils new Polyfoil mono-material barrier mini tubes
Small-size tubes enhance protection and versatility for pharmaceutical and oral care applications
Upcoming event
ISCC
15-18 October 2024 | Conference | Milan, Italy
See all
Related Content
Finance
Sobi enters into new distribution agreement with Valeant for Ammonul
The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
You need to be a subscriber to read this article.
Click here
to find out more.
Media
A precision medicine approach to developing cancer vaccines
Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Design & Build
Valeant Canada expands with $27.5m investment
The company will expand manufacturing and exporting capacity in Steinbach, Manitoba and Laval, Quebec
Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive
He brings more than 30 years of leadership and operations experience in healthcare to the firm
Valeant Pharmaceuticals makes management change
In its US Dermatology and Gastrointestinal businesses
J. Michael Pearson returns as CEO of Valeant following illness
Robert A. Ingram appointed Chairman of the Board as the roles of Chairman and CEO are separated
Regulatory
Opinion: Politics, passion and patient power
Did political correctness play a greater role than therapeutic efficacy in the FDA's decision to approve the 'pink Viagra'?
Subscribe now